Choose your country to see the products for your location
We have successfully obtained our certification under the new In Vitro Diagnostic Regulation (IVDR; 2017/746)! Very soon, the first batch of flagship products will be available on the market under the new IVDR, well in advance of the transition period deadline.
D007 Acute Lymphoblastic Leukemia just received an update, with version B1 featuring new probes that increase the coverage of ALL-relevant regions and target genes of emerging interest for ALL.
Effective from 1 January 2025, we will be implementing a price increase of approximately 1.9% on most of our products.
We have successfully obtained our certification under the new In Vitro Diagnostic Regulation (IVDR; 2017/746)! Very soon, the first batch of flagship products will be available on the market under the new IVDR, well in advance of the transition period deadline.
In the coming years we will update product descriptions for SALSA® MLPA® products that are for in vitro diagnostic (IVD) use to a new structure and layout.
Researchers from the University of Belgrade succeeded in making state-wide newborn screening become a reality through a stepwise plan that included a laboratory validation step, a feasibility study on a smaller cohort of newborns, and finally the transition to a national program.
Join our mailing list to receive the latest information about our products, technologies and website.